Literature DB >> 18621097

Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex.

Gerard J Marek1, Ce Zhang.   

Abstract

Serotonin and norepinephrine, in addition to direct postsynaptic excitatory effects, also enhances glutamate release onto layer V pyramidal cells of the prefrontal cortex/neocortex via G(q/11)-coupled 5-hydroxytryptamine(2A) (5-HT(2A)) and alpha(1)-adrenergic receptors, respectively. Therefore, the present study was designed to test whether a metabotropic glutamate (mGlu) receptor subtype also coupled to G(q/11)-proteins, the mGlu5 receptor, also induces EPSCs when recording from layer V cortical pyramidal cells of the rat medial prefrontal cortex (mPFC). The mGlu1/5 receptor agonist (S)-3,5-dihydroxyphenylglycine (DHPG) induces EPSCs at a similar frequency as a near-maximally effective 5-HT concentration. The mGlu5 receptor negative allosteric modulator 2-methyl-6-(phenylethynyl)pyridine (MPEP, 300 nM) potently blocked DHPG-induced EPSCs. Previous work has suggested that activation of 5-HT(2A) and OX2 receptors induces glutamate release, while mGlu2, mGlu4, and mGlu8 receptor activation suppress transmitter release from thalamocortical terminals. Taken together with past results, these findings suggest that mGlu2, mGlu4, mGlu5 and mGlu8 may all act to modulate glutamate release from afferents impinging on layer V pyramidal cells of the mPFC. These findings further suggest that monoamines, neuropeptides and glutamate itself all enhance the excitability of prefrontal cortical output cells indirectly via modulation of glutamate release.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18621097      PMCID: PMC2677702          DOI: 10.1016/j.neulet.2008.06.083

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  32 in total

1.  Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors.

Authors:  J C Gewirtz; G J Marek
Journal:  Neuropsychopharmacology       Date:  2000-11       Impact factor: 7.853

2.  DOI-Induced activation of the cortex: dependence on 5-HT2A heteroceptors on thalamocortical glutamatergic neurons.

Authors:  J L Scruggs; S Patel; M Bubser; A Y Deutch
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

3.  Group II metabotropic glutamate receptor modulation of DOI-induced c-fos mRNA and excitatory responses in the cerebral cortex.

Authors:  Yan Zhai; Carolyn A George; Jin Zhai; Eric S Nisenbaum; Michael P Johnson; Laura K Nisenbaum
Journal:  Neuropsychopharmacology       Date:  2003-01       Impact factor: 7.853

4.  Metabotropic glutamate autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro.

Authors:  L S Thomas; D E Jane; J R Harris; M J Croucher
Journal:  Neuropharmacology       Date:  2000-07-10       Impact factor: 5.250

5.  Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex.

Authors:  Evelyn K Lambe; Marina R Picciotto; George K Aghajanian
Journal:  Neuropsychopharmacology       Date:  2003-02       Impact factor: 7.853

6.  A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex.

Authors:  G J Marek; R A Wright; J C Gewirtz; D D Schoepp
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

7.  Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex.

Authors:  G J Marek; R A Wright; D D Schoepp; J A Monn; G K Aghajanian
Journal:  J Pharmacol Exp Ther       Date:  2000-01       Impact factor: 4.030

8.  Identification of a serotonin/glutamate receptor complex implicated in psychosis.

Authors:  Javier González-Maeso; Rosalind L Ang; Tony Yuen; Pokman Chan; Noelia V Weisstaub; Juan F López-Giménez; Mingming Zhou; Yuuya Okawa; Luis F Callado; Graeme Milligan; Jay A Gingrich; Marta Filizola; J Javier Meana; Stuart C Sealfon
Journal:  Nature       Date:  2008-02-24       Impact factor: 49.962

9.  Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors.

Authors:  Jonathan C Gewirtz; Andrew C Chen; Rose Terwilliger; Ronald C Duman; Gerard J Marek
Journal:  Pharmacol Biochem Behav       Date:  2002-09       Impact factor: 3.533

10.  Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice.

Authors:  Aleksandra Kłodzinska; Maria Bijak; Krzysztof Tokarski; Andrzej Pilc
Journal:  Pharmacol Biochem Behav       Date:  2002-09       Impact factor: 3.533

View more
  14 in total

1.  Examination of a role for metabotropic glutamate receptor 5 in the medial prefrontal cortex in cocaine sensitization in rats.

Authors:  Kristin M Timmer; Jeffery D Steketee
Journal:  Psychopharmacology (Berl)       Date:  2011-11-16       Impact factor: 4.530

2.  GABAergic signaling increases through the postnatal development to provide the potent inhibitory capability for the maturing demands of the prefrontal cortex.

Authors:  Jihong Cui; Fang Wang; Ke Wang; Hui Xiang
Journal:  Cell Mol Neurobiol       Date:  2009-11-17       Impact factor: 5.046

3.  Pain-related deactivation of medial prefrontal cortical neurons involves mGluR1 and GABA(A) receptors.

Authors:  Guangchen Ji; Volker Neugebauer
Journal:  J Neurophysiol       Date:  2011-08-31       Impact factor: 2.714

4.  CB1 augments mGluR5 function in medial prefrontal cortical neurons to inhibit amygdala hyperactivity in an arthritis pain model.

Authors:  Guangchen Ji; Volker Neugebauer
Journal:  Eur J Neurosci       Date:  2014-02       Impact factor: 3.386

5.  mGluR1, but not mGluR5, activates feed-forward inhibition in the medial prefrontal cortex to impair decision making.

Authors:  Hao Sun; Volker Neugebauer
Journal:  J Neurophysiol       Date:  2011-05-25       Impact factor: 2.714

Review 6.  The cannabinoid system and pain.

Authors:  Stephen G Woodhams; Victoria Chapman; David P Finn; Andrea G Hohmann; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

7.  mGluR5 Positive and Negative Allosteric Modulators Differentially Affect Dendritic Spine Density and Morphology in the Prefrontal Cortex.

Authors:  Amber L LaCrosse; Sara B Taylor; Natali E Nemirovsky; Justin T Gass; Michael F Olive
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

8.  Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1.

Authors:  Takaki Kiritoshi; Hao Sun; Wenjie Ren; Shaun R Stauffer; Craig W Lindsley; P Jeffrey Conn; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2012-04-06       Impact factor: 5.250

9.  Modulation of neuronal microcircuit activities within the medial prefrontal cortex by mGluR5 positive allosteric modulator.

Authors:  Marie Pollard; Jose Manuel Bartolome; P Jeffrey Conn; Thomas Steckler; Hamdy Shaban
Journal:  J Psychopharmacol       Date:  2014-07-16       Impact factor: 4.153

10.  Rescue of Impaired mGluR5-Driven Endocannabinoid Signaling Restores Prefrontal Cortical Output to Inhibit Pain in Arthritic Rats.

Authors:  Takaki Kiritoshi; Guangchen Ji; Volker Neugebauer
Journal:  J Neurosci       Date:  2016-01-20       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.